Last
Update:
July 30, 2015
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
XIX International AIDS Conference
|
Pharmacokinetics, safety and antiviral activity of
fosamprenavir/ritonavir-containing regimens in HIV-positive four
weeks
to < two year-old children (48-week data, study APV20002, a
prospective, open-label, multi-centre, 48-week cohort study)
M. Cotton, H. Cassim, N. Pavía-Ruz, et al
Abstract
HIV-1 drug
resistance and mutational profile in fosamprenavir-treated HIV-positive
children aged two months to 18 years at start of therapy
L. Ross, M. Cotton, H. Cassim, et al
Abstract
Pharmacokinetics, safety and antiviral activity of
fosamprenavir-containing regimens in HIV-positive 2 to 18 year-old
children (48-week data, Study APV29005, a prospective, open-label,
multi-centre, 48-week cohort study)
E. Voronin, C. Fortuny, D. Perez-Tamarit, et al
Abstract
6th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
POSTER
Use and safety of fosamprenavir in HIV-infected children in the European
Union: an ongoing
post-marketing surveillance study
A. Judd, L. E, L. Galli, T. Goetghebuer .et al
Poster
Abstract
- POSTER
A pilot study of the impact of switch to fosamprenavir and addition of
lovaza for treatment of hypertriglyceridemia in
HIV-infected subjects on antiretroviral therapy (ARVs)
F. Felizarta, A. Scarsella, H. Khanlou, et al
Poster
Abstract
- POSTER
Hepatic safety profile of fosamprenavir (FPV)-containing regimens in
HIV-1-infected subjects with or without hepatitis C
(HCV) or B (HBV) co-infection
B. Ha, B. Wine, M. Wisniewski,et al
Poster
Abstract
-
Pharmacokinetics,
cord blood concentrations, and tolerability of boosted fosamprenavir (FPV)
in pregnancy
M. Cespedes, S. Ford, G. Pakes, et al
Abstract
|
XIX
International AIDS Conference
Fosamprenavir Main Page
Main
New/Newsworthy
